ࡱ >
` bjbj$$ 0 F| F| ? B B 8 8 $ \ _ H ( 4 \ \ \ ! " D " $ _ _ _ _ _ _ _ $ a ?d ( 8_ - # v! v! @ # # 8_ \ \ e_ P( P( P( # R \ 8 \ X P( # _ P( P( M P \ p VE;v V# N ( nX {_ 0 _ N ge $ < ge P P P ge Q # # P( # # # # # 8_ 8_ P( # # # _ # # # # ge # # # # # # # # # B b : Q&A 56.7
What clinical evidence is there to support the use of Armour thyroid or other desiccated thyroid extract products?
Prepared by UK Medicines Information ( HYPERLINK "http://www.ukmi.nhs.uk/ukmi/about/default.asp?pageRef=1" UKMi) pharmacists for NHS healthcare professionals
Before using this Q&A, read the disclaimer at HYPERLINK "http://www.ukmi.nhs.uk/activities/medicinesQAs/default.asp" www.ukmi.nhs.uk/activities/medicinesQAs/default.asp
Date prepared: February 2016
Summary
Desiccated thyroid extract is derived from porcine thyroid gland. One grain contains 38mcg levothyroxine (T4) and 9mcg liothyronine (T3) per 65mg of the labelled amount of thyroid. Prescribers and patients should be aware that the amount of thyroid hormone in the thyroid gland can vary from animal to animal and between batches of product so a consistent effect cannot be guaranteed with desiccated thyroid extract products.
Products such as Armour Thyroid (AT), which contain thyroid extract, are not licensed in the UK. However, for historical reasons, these products are available in the US but they have not been approved by the US FDA as new drugs and have therefore not undergone rigorous clinical trials evaluating safety and efficacy. The FDA has urged companies who market unapproved drug products, including thyroid products, to carry out such studies and submit applications for their approval as new drugs.
The Royal College of Physicians (RCP), the British Thyroid Association and the European Thyroid Association all recommend that, for the vast majority of patients, levothyroxine alone is used in the treatment of hypothyroidism for underactivity of the thyroid gland. Routine use of thyroid extracts including AT is not recommended because this is inconsistent with normal physiology, they have not been unequivocally proven to be of any benefit to patients and they may be harmful in the long term. Most liothyronine (80%) is generated from the de-iodination of circulating T4, so a preparation of levothyroxine should provide T3 in a physiological and appropriate concentration.
There is a lack of good quality evidence to support the use of desiccated thyroid. Studies vary in design, size, duration and outcomes.
There is only one small randomised, controlled, crossover trial which has compared the efficacy of desiccated thyroid with levothyroxine.
Seventy patients were treated with one treatment for a period of 16 weeks, then crossed over to the other treatment for another 16 weeks. There was no difference in general health and all patients had TSH levels within range.
Patients who preferred desiccated thyroid (49%) tended to have greater weight loss and improvement in subjective symptoms such as concentration, memory and energy.
In a retrospective practice-based review, the use of desiccated thyroid improved symptoms in 89 patients who were previously uncontrolled on levothyroxine (median dose 76-100mcg). No dose titration of levothyroxine had been carried out prior to switching to desiccated thyroid to see if a dose increase could help with symptom control.
Another retrospective practice-based review found that switching to AT improved symptoms in 154 (euthyroid) patients who reported persistent symptoms despite taking levothyroxine. However, the patients studied were already dissatisfied with their levothyroxine which would have led to selection bias.
There is limited information regarding adverse events. Product information for desiccated thyroid products state that adverse reactions, other than those indicative of hyperthyroidism because of therapeutic overdosage, are rare. In a small study in which 40 patients had their treatment switched to levothyroxine from desiccated thyroid, abnormally high liothyronine concentrations, measured 2-5 hours post-dose were seen in 90% of patients taking 90mg-180mg desiccated thyroid. Most tolerated this well but six patients had symptoms of hyperthyroidism (nervousness, palpitations and tremor post-dose) and benefited from switching to levothyroxine. Abnormally high liothyronine levels were also seen in a smaller (n=21) case series.
Some patients do request treatment with desiccated thyroid, such as AT because they do not feel as well when treated with levothyroxine, but there is a lack of robust evidence supporting the clinical effectiveness of desiccated thyroid.
Background
Hypothyroidism is underactivity of the thyroid gland. The aim of treatment is to render the patient euthyroid, or with a normal thyroid state. ADDIN REFMGR.CITE Royal College of Physicians.20113666The diagnosis and management of primary hypothyroidism.Generic3666The diagnosis and management of primary hypothyroidism.Royal College of Physicians.2011armour thyroidIn Filehttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfAccessed 30/12/2013.http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfhttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf33(1) The Royal College of Physicians (RCP) recommend that, due to overwhelming evidence supporting its use, levothyroxine (tetra-iodothyronine, or T4) alone is used in the treatment of hypothyroidism. ADDIN REFMGR.CITE Royal College of Physicians.20113666The diagnosis and management of primary hypothyroidism.Generic3666The diagnosis and management of primary hypothyroidism.Royal College of Physicians.2011armour thyroidIn Filehttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfAccessed 30/12/2013.http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfhttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf33(1) Levothyroxine has a long half-life (1 week), giving relatively stable blood levels with minimal daily fluctuations in T4. Most liothyronine, T3, (80%), is generated from the de-iodination of circulating T4, so a preparation of levothyroxine should provide T3 in a physiological and appropriate concentration. ADDIN REFMGR.CITE Cooper19893719Thyroid hormone treatment: new insights into an old therapy.Journal3719Thyroid hormone treatment: new insights into an old therapy.Cooper,D.S.1989armour thyroidIn File26942695Journal of the American Medical Association26118Journal of the American Medical Association1(2) Liothyronine has a quicker onset (a few hours) and shorter duration of action than levothyroxine (half-life is 24-48 hours). (3-8)
The Royal College of Physicians (RCP), the British Thyroid Association (BTA) and the European Thyroid Association (ETA) all recommend that, for the vast majority of patients, levothyroxine alone is used in the treatment of hypothyroidism for underactivity of the thyroid gland. Routine use of thyroid extracts including AT is not generally recommended as this is inconsistent with normal physiology, has not been unequivocally proven to be of any benefit to patients and may be harmful in the long term. Furthermore, there are risks from T3 therapy, such as osteoporosis and arrhythmias (which can also occur with over-treatment of T4) and AT contains an excessive amount of T3 in relation to T4 (excessive compared to the normal physiological ratio of T3:T4 in human). (1,7,8)
Desiccated thyroid extracts, such as AT, NP Thyroid and Nature-Throid, are natural preparations derived from porcine thyroid glands. One grain of thyroid contains 38 micrograms (mcg) levothyroxine and 9mcg liothyronine per 65mg of the labelled amount of thyroid. ADDIN REFMGR.CITE ADDIN EN.CITE.DATA (3-5) The amount of thyroid hormone in the thyroid gland can vary from animal to animal and between batches (6) so a consistent effect cannot be guaranteed with desiccated thyroid extract products. These products are not licensed in the UK and while they are available in the US, (3-5) they have not been approved by the US FDA as new drugs and have therefore not undergone rigorous clinical trials evaluating safety and efficacy. Notably, the FDA have urged all companies who market unapproved drug products, including thyroid products, to carry out such studies and submit applications for approval but to date; no such applications have been submitted at the time of writing.
The use of desiccated thyroid is considered by some to be obsolete and is not supported by the RCP due to the lack of supporting validated research in published in peer-reviewed journals. ADDIN REFMGR.CITE ADDIN EN.CITE.DATA (1,6,9-11). There is also some concern that symptoms of hyperthyroidism, due to high T3 levels post-dose, can occur. ADDIN REFMGR.CITE ADDIN EN.CITE.DATA (2;6,9,10) However, some patients do request treatment with desiccated thyroid, such as AT because they do not feel as well when treated with levothyroxine ADDIN REFMGR.CITE Hoang20133674Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.Journal3674Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.Hoang,T.D.Olsen,C.H.Mai,V.Q.Clyde,P.W.2013armour thyroidIn File19821990J.Clin.Endocrinol.Metab.985Journal of Clinical Endocrinology and MetabolismJ.Clin.Endocrinol.Metab.1(12), but are there any robust data to support the clinical effectiveness of desiccated thyroid?
Answer
Few robust studies of desiccated thyroid have been carried out in the last 10 years. Most data are pre-1980 and many studies date from the 1950s to 1970s. These tend to be uncontrolled, open-label studies which compared desiccated thyroid with levothyroxine, not in terms of efficacy and safety but comparative potency, onset and duration of action, and effects on serum lipids; these have not been included in this Q&A. ADDIN REFMGR.CITE ADDIN EN.CITE.DATA (13-16) It is not clear whether studies comparing levothyroxine alone with levothyroxine/T3 combination can be extrapolated to desiccated thyroid. These studies have not been reviewed because they do not provide information supporting the clinical effectiveness of natural desiccated thyroid.
Randomised, double-blind trial
There is only one randomised, prospective, double-blind study comparing the effectiveness of desiccated thyroid extract (DTE) with levothyroxine (n=70). ADDIN REFMGR.CITE Hoang20133674Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.Journal3674Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study.Hoang,T.D.Olsen,C.H.Mai,V.Q.Clyde,P.W.2013armour thyroidIn File19821990J.Clin.Endocrinol.Metab.985Journal of Clinical Endocrinology and MetabolismJ.Clin.Endocrinol.Metab.1(12) Patients with primary hypothyroidism on a stable dose of levothyroxine were randomised to treatment with either DTE or levothyroxine in identical appearing capsules. Each grain (65mg) of DTE (as AT) provided 38mcg levothyroxine and 9mcg liothyronine. The initial desiccated thyroid dose was based on the conversion: 1mg DTE = 1.667mcg levothyroxine. After 6 weeks of study medication, thyroid stimulating hormone (TSH) levels were checked and medication adjusted to maintain TSH between 0.5 and 3.0microIU/mL. Once the TSH was within range, medication was continued for at least another 12 weeks. Patients were then crossed over to the other treatment arm for 16 weeks, with TSH checked at 6 weeks as during the first treatment period.
The primary outcome measures were the changes from baseline to endpoint of a number of assessments, including the Thyroid Symptom Questionnaire (TSQ), the quality of life General Health Questionnaire (GHQ)-12, the Wechsler memory scale (WMS-IV) and the Beck Depression Inventory (BDI). The WMS-IV included the auditory memory index (AMI) and the visual working memory index (VWMI). Subgroup analyses were carried out on patients who preferred desiccated thyroid or levothyroxine or who had no preference. A sample size of 67 was required to provide 80% power to detect a difference of 8 points on the TSQ.
Primary outcome measures. Overall, the patients showed no difference in symptom scores, general health questionnaires or neuropsychological testing. During the DTE treatment period, there was a trend towards greater improvements in GHQ-12, TSQ and AMI and there was a reduction of 2.86lb in weight (p<0.001) compared to the levothyroxine treatment period. No study patient had a TSH level outside of the reference range. No adverse events were reported with any of the treatments; both were tolerated equally well. Patients had higher T3 serum levels during the DTE treatment period but no cardiovascular adverse events occurred.
Patient preference. At the end of the study, 34 patients (49%) preferred DTE treatment, 13 (19%) preferred levothyroxine and 23 (33%) had no preference. The higher preference for DTE therapy was due to an average of 4lb weight loss during the DTE treatment compared with levothyroxine (p<0.001), (note that on average, these patients were 16lbs heavier at baseline than those patients who preferred levothyroxine), and improvements in subjective symptoms such as concentration, memory, sleep, decision-making capability, happiness and energy levels. Patients preferring DTE therapy did better on their neuropsychological measures compared with baseline [TSQ, GHQ-12 WMS-IV and BDI], while those preferring levothyroxine did better only on the WMS-IV.
Predictors of preference for DTE. The best predictor for clinical preference for DTE was a lower TSQ score at endpoint. Patients with lower VWMI values on DTE were also more likely to favour DTE.
Doses. The mean levothyroxine dose during the study was 119.2mcg and the mean DTE dose was 80.6mg.
For the patients who preferred DTE treatment, their general well-being and thyroid symptoms were better controlled than with levothyroxine. It is possible that DTE may provide subtle improvements for some patients. The study is limited by its small size, low sensitivity of some of the neuropsychological tests and biochemical measures, no genetic testing for deiodinase polymorphisms and the lack of a washout period, although this may not have been deemed appropriate. Studies with a longer duration are required to clarify the efficacy and safety of desiccated thyroid extract.
Switching from desiccated thyroid to levothyroxine
Thyroid hormone levels were compared in 40 patients who had their therapy switched from desiccated thyroid to levothyroxine and clinical benefits were assessed. ADDIN REFMGR.CITE Jackson19783667Why does anyone still use desiccated thyroxine USP?Journal3667Why does anyone still use desiccated thyroxine USP?Jackson,I.M.Cobb,W.E.1978armour thyroidIn File284Am.J.Med.197864American Journal of MedicineAm.J.Med.1(6) Seventeen patients had been treated for hypothyroidism and 23 patients received thyroid as medical therapy for thyroid gland suppression. The most common desiccated thyroid doses were 120mg-180mg per day (in 35/40 patients), which were switched to 150mcg to 200mcg levothyroxine daily. Serum thyroid hormone levels were measured while the patients were taking desiccated thyroid, and then at least 6 weeks after changing to levothyroxine. The mean T3 levels with desiccated thyroid were significantly higher than with levothyroxine: 289ng/dL vs. 176ng/dL, p<0.0005 [normal range, 70-180ng/dL]. The mean T4 level was significantly lower with desiccated thyroid than with levothyroxine: 7.4mcg/dL vs. 11.6mcg/dL, p<0.01 [normal range, 5-13mcg/dL].
When treated with desiccated thyroid, most patients (36/38) had T3 levels above the normal range and 39/40 had T4 levels in the low normal or normal range; raised T4 level was seen in a pregnant patient. One patient had a T3 level of 540ng/dL 3 hours post-dose, falling to 240ng/dL at 24 hours; supraphysiological levels of T3 have also been reported in a case series of 21 patients experiencing nervousness, palpitations and tremor post-dose. ADDIN REFMGR.CITE Lev-Ran19833677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Journal3677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Lev-Ran,A.1983armour thyroidIn File27902791Journal of the American Medical Association25020Journal of the American Medical Association1(9)
When treated with levothyroxine, 17/40 patients had elevated T3 levels (two of the 17 patients had previously been taking 60mg desiccated thyroid) and 8/40 had raised T4 levels; three of the raised T3 and one of the raised T4 could be accounted for by pregnancy and all of the raised levels occurred in patients taking 200mcg, which may have been too high a dose.
What this study showed is that symptoms of hyperthyroidism may occur following a daily dose of 120-180mg desiccated thyroid. Abnormally high T3 concentrations, measured 2-5 hours post-dose were seen in 90% of patients taking 90mg-180mg desiccated thyroid; while most tolerated this well, six patients had symptoms of hyperthyroidism and benefited from switching to levothyroxine. Raised T3 levels may be hazardous in some patients, especially those with cardiac disease. Changing to levothyroxine resulted in lower T3 and higher T4 levels, resembling those seen in normal subjects.
Retrospective, practice-based reviews
Two retrospective practice based reviews assessing the symptomatic effects of switching from levothyroxine to a desiccated thyroid treatment were identified.
In the first, published in 1997, the records of 89 patients with hypothyroidism treated with levothyroxine but still symptomatic were compared with those of 832 untreated hypothyroid patients. ADDIN REFMGR.CITE Baisier19973673Thyroid insufficiency. Is thyroxine the only valuable drug?Journal3673Thyroid insufficiency. Is thyroxine the only valuable drug?Baisier,W.V.Hertoghe,J.Eeckhaut,W.1997armour thyroidIn File159166J Nutr Environ Med11J Nutr Environ Med1(17) Forty of the previously treated patients and 278 of the untreated patients were followed-up after treatment with natural desiccated thyroid. The investigators monitored eight main symptoms, (constipation, headache, muscle cramps, depression, Achilles, rheumatoid, cold, fatigue), scored as 0=no symptoms and 2=full-blown symptoms, giving a maximum score of 16.
In the levothyroxine-treated patients prior to switching to desiccated thyroid (n=40), the prevalence of symptoms was comparable to that of the main group of untreated patients, with a mean symptom score of 10.7. The mean 24-hour urine free T3* level was 797.5pmol. The mean levothyroxine dose was 99.7mcg, given for a mean 33.2 months; most patients were taking between 76-100mcg/day.
After switching to desiccated thyroid treatment, the mean symptom score fell from 10.7 to 3.6 and the mean 24-hour urine T3 rose from 767 to 1990pmol. Mean desiccated thyroid dose was 233mg, given for a mean 26.9 months.
For the previously untreated patients, the mean symptom score fell from 10.1 to 3.6 and the 24-hour urine T3 rose from 752 to 1900pmol. The mean desiccated thyroid dose was 200mg, given for a mean 23 months.
The investigators acknowledge that levothyroxine treatment can adequately treat patients with hypothyroidism. They also state that reliance on serum tests (thyroid stimulating hormone and free T4) than on clinical signs and 24-hour urine free T3 may lead to an insufficient dose of thyroid hormone to obtain satisfactory results. But, the investigators did not appear to consider the possibility that the 89 patients still symptomatic on levothyroxine may have simply required a dose increase to control their symptoms, but instead switched them to desiccated thyroid. For all patients, the 24-hour urine free T3 levels were low but were within the reference range. The study is limited by its retrospective nature, lack of control group and lack of titration of levothyroxine to control symptoms.
* A 24-hour urine free T3 measured below the reference range indicates functional hypothyroidism. Free T3 measures the biologically active fraction of total T3, the majority of which is bound by protein carriers and is therefore inactive. The normal range is 592 1850pmol/24 hours.
Another retrospective review (described as a retrospective observational study) was published in 2014. (18) It investigated the observed preference for AT over levothyroxine in a subgroup of patients with hypothyroidism who reported dissatisfaction with levothyroxine monotherapy. Of the 450 patients treated at a single outpatient endocrinology practice over 3 months, 154 patients (34%, average age 53 years) self-reported failure of levothyroxine monotherapy. Despite having normal thyroid hormone levels, they reported persistent fatigue, cold intolerance, constipation, myalgia and unexplained weight gain. (17)
They were switched from levothyroxine (average dose prior to switch not documented) to AT (mean dose post switch 92.3 +/- 28.6mg), excluding those with thyroid cancer or nodular thyroid therapy. It is not clear from the manuscript whether the dose of levothyroxine was optimised prior to switching. After at least 4 weeks on AT, patients were asked to compare AT and levothyroxine using a 5 point patient Satisfaction Rating Scale (=SRS, where 1 mea n s t h a t A T i s d e f i n i t e l y w o r s e t h a n l e v o t h y r o x i n e a n d 5 m e a n s t h a t A T i s d e f i n i t e l y b e t t e r t h a n l e v o t h y r o x i n e ) .
O f t h e 1 5 4 p a t i e n t s s w i t c h e d , 7 8 % s c o r e d > 3 a n d t h e y w e r e c l a s s e d a s r e s p o n d e r s . T h i r t y t h r e e p a t i e n t s ( 2 1 % ) s c o r e d d"3 ; t h e y w e r e c l a s s e d a s non-responders. The average mean SRS scores for responders vs. non responders was 4.79 vs. 2.70, p<0.001. TSH levels checked after the switch did not differ to levels taken before the switch (1.30 vs. 1.34 mIU/L, p=ns). T3 levels, however, increased after the switch (1.18 vs. 1.50 pmol/L, p<0.003) and the T4:T3 ratio was lowered when patients were switched (4.70 vs. 8.45, p<0.001). Despite this, reported patient satisfaction and biochemistry did not correlate and there was no significant change in average weight after switching (75.9kg vs. 74.4kg).No adverse reactions were reported.
This study suggests that in patients already dissatisfied with their hypothyroid symptom management with levothyroxine despite being biochemically euthyroid, switching to AT increases their level of perceived satisfaction. Larger, prospective studies with a suitable control group are needed to clarify whether AT has a role in the management of hypothyroidism. There were several limitations; although a relatively high proportion of patients (78%) reported satisfaction with the switch from levothyroxine to AT, this is the expected result of a selection bias for patients already dissatisfied with levothyroxine treatment. The study did not involve any blinding which would have compounded this bias. The study was relatively small and of short duration and the five point SRS scale used is not a validated scale. Furthermore, the paper is published in an open access journal and there are small discrepancies between the numerical results published in the abstract and the main text. Given the discrepancies and noting that such journals often charge authors a fee for publication, there is concern about whether the manuscript of the study was adequately peer reviewed prior to publication. (18,19)
Limitations
This Q&A focuses solely on the use of desiccated thyroid for the treatment of hypothyroidism, not euthyroid hypometabolism.
This Q&A focuses on evidence that shows clinical effectiveness and safety of AT compared with that of levothyroxine.
There may be articles that were not found via the three databases searched (Embase, Medline and AltMedDex). This may be because either the journal is not included in the 3,500+ journals indexed by these databases, or that the article was published prior to 1950 and as such, that practice may be considered obsolete.
References
ADDIN REFMGR.REFLIST (1) The diagnosis and management of primary hypothyroidism. Royal College of Physicians. HYPERLINK "http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf" http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf Accessed 08/01/2016.
(2) Cooper DS. Thyroid hormone treatment: new insights into an old therapy. Journal of the American Medical Association 1989; 261(18):2694-2695.
(3) Armour thyroid (thyroid tablets, USP). Forest Pharmaceuticals, Inc. http://pi.actavis.com/data_stream.asp?product_group=1924&p=pi&language=E Accessed 08/01/2016.
(4) NP Thyroid (thyroid tablets, USP). Acella Pharmaceuticals, LLC. http://www.npthyroid.com/assets/ace-15666-pi.pdf Accessed 08/01/2016.
(5) Nature-Throid (thyroid USP) tablets. RLC Labs http://getrealthyroid.com/wp-content/uploads/2014/11/Nature-Throid-Prescribing-Information.pdf Accessed 19/2/16
(6) Jackson IM, Cobb WE. Why does anyone still use desiccated thyroxine USP? Am J Med 1978; 1978(64):-284.
(7) Wiersinga WM, Duntas L, Fadeyev V et al. 2012 ETA Guidelines: The use of L-T4 + L-T3 in the treatment of hypothyroidism. European Thyroid Journal 2010; 1: 55-71
(8) Okosieme O, Gilbert J, Abraham P et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clinical Endocrinology 2015; 0: 1-10
(9) Lev-Ran A. Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid. Journal of the American Medical Association 1983; 250(20):2790-2791.
(10) Smith SR. Desiccated thyroid preparations. Obsolete therapy. Arch Intern Med 1984; 144:926-927.
(11) Vaidya B, Pearce SHS. Management of hypothyroidism in adults. Br Med J 2008; 337:284-289.
(12) Hoang TD, Olsen CH, Mai VQ et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a randomized, double-blind, crossover study. J Clin Endocrinol Metab 2013; 98(5):1982-1990.
(13) Sawin CT, Hershman JM, Fernandez-Garcia R et al. A comparison of thyroxine and desiccated thyroid in patients with primary hypothyrodism. Metabolism 1978; 27(10):1518-1525.
(14) Singh SP, Feldman EB, Carter AC. Desiccated thryoid and levothyroxine in hypothyroidism. N Y State J Med 1972; May:1045-1048.
(15) Sturnick MI, Lesses MF. A comparison of the effect of desiccated thyroid and sodium levothyroxine on the serum protein-bound iodine. N Engl J Med 1961; 264(12):608-609.
(16) McGavack TH, Reckendorf HK. Therapeutic activity of desiccated thyroid substance, sodium L-thyroxine and D,L-triiodothyronine. A comparative study. Am J Med 1956; May:774-777.
(17) Baisier WV, Hertoghe J, Eeckhaut W. Thyroid insufficiency. Is thyroxine the only valuable drug? J Nutr Environ Med 1997; 11:159-166.
(18) Pepper GM, Casanova-Romero PY. Conversion to Armour Thyroid from Levothyroxine improved patient satisfaction in the treatment of hypothyroidism. Journal of Endocrinology, Diabetes and Obesity 2014; 2 (3):1055.
(19) Butler D, The dark side of publishing, Nature 2013; 495: 433-5.
Quality Assurance
Updated by
Sheena Vithlani, Regional MI Manager, London Medicines Information Service, Northwick Park Hospital, Harrow.
Date Prepared
11/02//2016
Checked by
Elizabeth Uhegwu, Medicines Information Pharmacist, London Medicines Information Service, Northwick Park Hospital, Harrow. Date of check
23/02/2016
Contact
HYPERLINK "mailto:lnwh-tr.medinfo@nhs.net" lnwh-tr.medinfo@nhs.net
Search strategy
NICE Evidence ( HYPERLINK "http://www.evidence.nhs.uk" www.evidence.nhs.uk), NICE ( HYPERLINK "http://www.nice.org.uk" www.nice.org.uk), SIGN ( HYPERLINK "http://www.sign.ac.uk" www.sign.ac.uk), Cochrane Database, Royal College of Physicians (www.rcplondon.ac.uk/) , British Thyroid Association ( HYPERLINK "http://www.britishthyroid-association.org" www.britishthyroid-association.org), MHRA ( HYPERLINK "http://www.mhra.gov.uk" www.mhra.gov.uk), FDA (www.fda.gov), Micromedex (www.micromedexsolutions.com ), BNF, Martindale and AHFS (via HYPERLINK "http://www.medicinescomplete.com" www.medicinescomplete.com),
Internet Search: HYPERLINK "http://www.google.co.uk" www.google.co.uk, armour thyroid desiccated thyroid, natural thyroid
Embase (1980-present), Medline (1950-present) and AltMedDex (1985-present): Date of search: 08/10/2013 via NHS Evidence.
1EMBASE(armour AND thyroid).af HYPERLINK "http://www.library.nhs.uk/hdas/search-results/1?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 3292EMBASE"armour thyroid".af (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/2?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 23 (5) 3EMBASE"desiccated porcine thyroid".af (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/3?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 1 (0)4EMBASE"porcine thyroid".af (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/4?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 526 (10)5EMBASE4 [Limit to: Human and English Language] HYPERLINK "http://www.library.nhs.uk/hdas/search-results/5?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 92 6EMBASEHYPOTHYROIDISM/ [Limit to: Human and English Language] (last 2 years)29888 (6858)7EMBASE5 AND 6 [Limit to: Human and English Language] (last 2 years)23 ( HYPERLINK "http://www.library.nhs.uk/hdas/search-results/7?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 11) 8EMBASE"dessicated thyroid".af (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/8?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 11 (0)9EMBASE"desiccated thyroid".af (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/9?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 103 (6)10EMBASE8 OR 9 (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/10?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 114 (6) 11EMBASE10 [Limit to: Human] (last 2 years) HYPERLINK "http://www.library.nhs.uk/hdas/search-results/11?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 70 (14) 12MEDLINE(desiccated AND thyroid).af HYPERLINK "http://www.library.nhs.uk/hdas/search-results/12?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 176 13MEDLINE"desiccated thyroid".af HYPERLINK "http://www.library.nhs.uk/hdas/search-results/13?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 132 14MEDLINE(dessiccated AND thyroid) OR (dessicated AND thyroid) OR (desicated AND thyroid) or (armour thyroid) OR (armour thyroid)2515MEDLINETHYROID HORMONES1716716MEDLINEHYPOTHYROIDISM/ DT,PC [DT = drug therapy, PC = prevention and control). (last 2 years) 415217MEDLINE(12 OR 13 OR 14 OR 15) AND 16 (last 2 years) 196 (1)18AMED"desiccated thyroid".af HYPERLINK "http://www.library.nhs.uk/hdas/search-results/15?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 1 19AMED"armour thyroid".af HYPERLINK "http://www.library.nhs.uk/hdas/search-results/16?PageNumber=1&PageSize=50&SortBy=srt.unspecified&ShowAbstracts=True&databases=bnj.ovi.amed" 1 20AMEDarmour AND thyroid.af121AMEDHYPOTHYROIDISM/ OR THYROID HORMONES/80
PAGE
PAGE 1
Available through NICE Evidence Search at HYPERLINK "http://www.evidence.nhs.uk" www.evidence.nhs.uk
Medicines Q&As
? @ A B G O T Z d l t } ~ нq^K^8 $h i h< 5B*CJ ^J aJ ph $h i h\0 5B*CJ ^J aJ ph $h i hVOJ 5B*CJ ^J aJ ph $h i hm^ 5B*CJ ^J aJ ph $h i hPKW 5B*CJ ^J aJ ph $h i h' 5B*CJ ^J aJ ph $h i hf 5B*CJ ^J aJ ph $h i h| 5B*CJ ^J aJ ph h i h< ^J h i h7_ CJ ^J aJ h i hD CJ ^J aJ h i h< CJ ^J aJ
"
; P Q :
& F
V^`Vgdd<
& F
V^`Vgdd< ^gdS
& F V^`Vgdd<
& F V^`Vgdoh $a$gd- gd- $a$gd
" P Q ղ椓ynaTG h i h7_ CJ ^J aJ h i hot CJ ^J aJ h i h| CJ ^J aJ h i h< B*
ph 3f h i h< 0J CJ ]^J h i h< CJ ]^J j h i h< CJ U]^J h i h< 6CJ ]^J h i h< 0J CJ ^J aJ 'j h i h< CJ U^J aJ !j h i h< CJ U^J aJ h i h< CJ ^J aJ h i h)q[ CJ ^J aJ b
c
}
~
,
5 D t ~sdYNsYs~ h i h3 CJ ^J h i h c' CJ ^J h i h3 0J OJ QJ tH h i h_&2 CJ ^J h i h6 CJ ^J h i hS~ CJ ^J h i hC @ CJ ^J h i hoh CJ ^J h i h0K CJ ^J h i hSxW CJ H*^J h i hSxW CJ ^J h i hAa 5B*CJ ^J ph $h i hAa 5B*CJ ^J aJ ph hS 5B*CJ ^J aJ ph t y Z [ ^ c r ; O P Q V 9 ( ꔉv̟vkh i hIw CJ ^J h i hS CJ ^J h CJ ^J h i hG CJ ^J h i h 2$ CJ ^J h i h CJ ^J h i h6 CJ H*^J h i hW4 CJ ^J h i h_&2 CJ ^J hS CJ ^J h i h5 5 CJ ^J h i h\o CJ ^J h i h6 CJ ^J h i h@+ CJ ^J * 3 ` C 2 3 4 ? O( P( \+ ]+ =/ >/ <6 =6 D6 @9 A9 `9 [A \A C C gdil gdS gd-
& F V^`Vgdd<
^gdS ( 1 = @ 3 j z 7 > ] _ ` G B C 2 3 ɾɾɳɾɾɾɳɨ|i $h i h2 5B*CJ ^J aJ ph h i hM CJ ^J h i hyq CJ ^J h i h~ CJ ^J h i h5 5 CJ ^J h i hG CJ ^J h i h\; CJ ^J h i h+ CJ ^J h i hAE9 CJ ^J h i h CJ ^J h i h@+ CJ ^J h i h CJ ^J h i h
P CJ ^J #3 4 > ? u > ? B C E v# w# z# {# }# # # uffVfK? h i h{y CJ H*^J h i h{y CJ ^J h i hV{ CJ ^J mH nH u j h i hV{ CJ U^J h i h(- CJ H*^J h i h(- CJ ^J h i hs\ CJ ^J mH nH uh i hW4 CJ ^J j h i hs\ CJ U^J h i hs\ CJ ^J h i h
d CJ ^J h i h< 5B*CJ ^J ph $h i h< 5B*CJ ^J aJ ph hS 5B*CJ ^J aJ ph # # $
$ .$ /$ J$ K$ $ $ $ $ $ ' ' ' ' ' ' ' ' ' -( 6( H( N( O( P( u( w( ) ȹ}}rgrgXg h i hil 0J OJ QJ tH h i hil CJ ^J h i h2 CJ ^J h i h f CJ ^J h i hC+ CJ ^J h i h8 CJ ^J h i h_&2 CJ ^J mH nH uh i hW4 CJ ^J j h i h_&2 CJ U^J h i hv CJ ^J h i h"\ CJ ^J h i h_&2 CJ H*^J h i h_&2 CJ ^J h i h{y CJ ^J ) ) ) ) ) ) 5* F* G* H* U* j* k* l* * * * * * * * * * + + + C+ D+ F+ G+ Q+ R+ V+ ɾɳ골znbWbWbW h i h^ CJ ^J h i h^ CJ H*^J h i hs\ CJ H*^J h i hC @ CJ ^J h i h2/ CJ H*^J h i h2/ CJ ^J h i h_&2 CJ H*^J h i h_&2 CJ ^J h i hs\ CJ ^J h i hM) CJ ^J h i hV{ CJ ^J h i h F CJ ^J h i h CJ ^J h i hil CJ ^J h i h(- CJ ^J V+ Y+ \+ ]+ i+ + + + + + + + + + , , -, 9, d, e, f, g, z, {, , , , , ɾɳɳɨɠɕɊ{papOa{ #j h i hW4 CJ U^J j h i hW4 CJ U^J h i hW4 CJ ^J j h i hZ CJ U^J h i hv CJ ^J h i h~] CJ ^J hGg CJ ^J h i hSxW CJ ^J h i h, CJ ^J h i hC @ CJ ^J h i hZ CJ ^J h i h6 CJ ^J h i hf CJ ^J h i hil CJ ^J h i h CJ ^J , , , , , , , - - X- Z- - - - A. B. w. y. . . . . #/ :/ / / ʿʞ}rg}\Q h i hXE CJ ^J h i hh CJ ^J h i hf CJ ^J h i h^ CJ ^J h i hR~g CJ ^J h i hVOJ CJ ^J h i hW4 CJ ^J h i hu CJ ^J h i hM) CJ ^J h i h CJ ^J h i hil CJ ^J h i hc CJ ^J h i hZ CJ ^J j h i hZ CJ U^J h i h{y CJ ^J mH nH u / /
0 0 "0 #0 $0 %0 '0 .0 /0 00 10 20 30 0 0 0 0 0 0 0 0 0 0 0 0 0 0 xm^L^^x #j h i hW4 CJ U^J j h i h|I CJ U^J h i h7Q CJ ^J h i h|I CJ ^J h i h CJ ^J h i hN CJ ^J h i hXE CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH u#je
h i hW4 CJ U^J j h i hW4 CJ U^J h i hW4 CJ ^J j h i hXE CJ U^J 0 0 0 1 !1 #1 d1 e1 f1 5 5 5 5 5 5 5 5 '6 96 <6 =6 C6 ɾyncXO< $h i h< 5B*CJ ^J aJ ph h i h< ^J h i h
d CJ ^J h i hX
CJ ^J h i hV CJ ^J h i h:B CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH uh i hW4 CJ ^J j h i hf CJ U^J h i hf CJ ^J h i h Gi CJ ^J h i hC @ CJ ^J h i h3
CJ ^J h i hA CJ ^J h i h F CJ ^J C6 D6 E6 m6 ~6 6 6 6 6 6 6 6 6 6 6 7 7 7 !7 7 7 7 7 7 7 7 7 7 7 8 teZKZ j h i hW4 CJ U^J h i hW4 CJ ^J j h i h[| CJ U^J h i h\0 CJ ^J h i hil CJ ^J h i h[| CJ ^J h i hy/ CJ ^J h i h CJ ^J h i h :Q CJ ^J h i h F CJ ^J h i hA CJ ^J h i h^ CJ ^J h i hn CJ ^J h i h{Qn CJ ^J $h i h"\ 5B*CJ ^J aJ ph 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 "9 *9 >9 ?9 @9 A9 L9 Z9 ϿϤxmbWK? h i hq 5CJ ^J h i h? 5CJ ^J h i h? CJ ^J h i hn CJ ^J h i hy/ CJ ^J h i h"\ CJ ^J h i h( CJ ^J h i hO7 CJ ^J h i h[| CJ ^J h i h\0 CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH u j h i h[| CJ U^J j h i hW4 CJ U^J #j' h i hW4 CJ U^J Z9 _9 `9 ~9 9 9 9 9 9 9 9 9 l> m> o> p> q> r> t> }> > > > 0? 5? :? ;? b? c? q? ? ? ? 踭wlaV h i h_&2 CJ ^J h i hj CJ ^J h i hC @ CJ ^J h i h)\ CJ ^J h i hN CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH uh i hW4 CJ ^J j h i h? CJ U^J h i hH CJ ^J h i h CJ ^J h i hq CJ ^J h i h? CJ ^J h i h+k 5CJ ^J ? @ @ @ @ @ ZA [A )B ,B zB B B B B B 6C jC kC C C C C C VD xD D D ɾɳɝ|pe|eZO h i h*3h CJ ^J h i h;N CJ ^J h i h* CJ ^J h i h* 6CJ ^J h i h)\ CJ ^J h i h T' CJ ^J h i hYV CJ ^J h i h CJ ^J h i h?[U CJ ^J h i h?( CJ ^J h i ha CJ ^J h i h CJ ^J h i h? CJ ^J h i h CJ ^J h i hq CJ ^J h i h)? CJ ^J D D D D D D D D D E E E #E HE gE hE E 8F 9F :F MF NF F G G aG dG nG xG G G G G bH ɾɨɝ{pepZZZZp h i hR2] CJ ^J h i h
8k CJ ^J h i h3} CJ ^J h i h* 6CJ ^J h i h* CJ ^J h i h2e CJ ^J h i hJo CJ ^J h i h6 CJ ^J h i h l CJ ^J h i h7Q CJ ^J h i h/ CJ ^J h i h;N CJ ^J h i h?( CJ ^J h i h*3h CJ ^J h i hH CJ ^J !C :F +I I XJ YJ L L L S S X Y Y 9\ :\ `\ \ ] \b ]b c d e
& F gdM>:
& F gd*
& F ^gd- gd( gdn
& F 7L^7`Lgd_F bH H H *I +I LI I I I I I I I I RJ TJ VJ WJ XJ YJ 2K XK K 2L L L L L L M uM ȼȱȦțzncXc h i hon CJ ^J h i h1 CJ ^J h i hk_ 5CJ ^J h i hR2] CJ ^J h i h: CJ ^J h i hhf CJ ^J h i hn CJ ^J h i hD CJ ^J h i h
8k CJ ^J h i hJo 6CJ ^J h i hJo CJ ^J h i h?( 6CJ ^J h i h?( CJ ^J h i h6I CJ ^J h i hz CJ ^J uM vM P P P P P P P Q Q 0Q AQ YQ wQ xQ Q Q Q _R R R R S S xmxbWbL@ h i h`> CJ H*^J h i h`> CJ ^J h i h. CJ ^J h i hkR CJ ^J h i hD CJ ^J h i hr;n CJ ^J h i hOe CJ ^J h i hRL CJ ^J h i hv CJ ^J h i hTW CJ ^J h i h=" CJ ^J h i h1 CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH uh i hW4 CJ ^J j h i h1 CJ U^J S vS S S S S S S S S S 0T 2T :T ;T uT vT wT T T T T RU SU xX yX zX {X |X }X X ɽɲɚɲɏɀueUe h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH uh i hW4 CJ ^J j h i hU- CJ U^J h i hOe CJ ^J h i hU- CJ H*^J h i h_&2 CJ H*^J h i h_&2 CJ ^J h i hU- 6CJ ^J h i hU- CJ ^J h i h( CJ ^J h i hv CJ ^J h i h. CJ ^J h i h`> CJ ^J X X X X X X X X X X Y (Y )Y FY GY HY `Y aY Y Y Y }Z ~Z Z Z Z k[ t[ u[ v[ [ [ [ [ \ \ 8\ :\ ^\ 꼱꼚ǼǏǼxl h i h"< 5CJ ^J h i h+ CJ ^J h i hv CJ H*^J h i h`? CJ ^J h i h( CJ ^J h i hU- CJ H*^J h i hOe CJ ^J h i hv CJ ^J h i h_&2 CJ H*^J h i h_&2 CJ ^J h i hU- 6CJ ^J h i hU- CJ ^J h i h- CJ ^J &^\ _\ `\ "] ] ] ` ` ` ` ` ` ` ` \b ]b db yb b b
c )c ,c 4c Pc øèÍwlaUawawJw? h i h_&2 CJ ^J h i hzv CJ ^J h i h=( 6CJ ^J h i h=( CJ ^J h i h( CJ ^J h i hM>: CJ ^J h i h9# CJ ^J h i h# CJ ^J h i h7Q CJ ^J mH nH u h i hW4 CJ ^J mH nH uh i hW4 CJ ^J j h i h# CJ U^J h i h Z CJ ^J h i h7_ CJ ^J h i h CJ ^J h i h7_ 5CJ ^J Pc Qc fc ic c c c c c c d [d \d ]d zd d d d d *e +e ,e He Se me ne re e e e e f 輱ұ҄yұncX h i h
p CJ ^J h i h_Q CJ ^J h i h( CJ ^J h i hOe CJ ^J h i hn( CJ ^J h i hV& CJ ^J h i h_&2 CJ ^J h i hM>: 6CJ ^J h i hM>: CJ ^J h i h; CJ ^J h i h1A CJ ^J h i h CJ ^J h i h=( CJ ^J h i h' CJ ^J h i h_&2 CJ H*^J e e h h i i ?l @l n n Or Pr w w w w x Ey Fy Ry { { E|
V( ^`Vgd f gdf
& F
gdV,
& F
gdI gdmO gd gdX1b gd' f 6f Uf Vf f f f g g g g g g h h h h h 0h h h h h i i Ui Vi i i i i i &j ;j k @k Lk Uk qk vk k k k :l >l ?l @l El fl l l l l m km rm ym zm m m m m m m m m m m m m Hn fn n n n n n o o ɾɾɾԾɨߨߨ h i h6} h i hmf h i hmf CJ ^J h i h;U CJ ^J h i hR~g CJ ^J h i h CJ ^J h i hC @ CJ ^J h i hm CJ ^J h i h7_ CJ ^J h i h+ CJ ^J < o 4o :o *CJ U^J mH nH u"h i hW4 >*CJ ^J mH nH u +j h i hW4 >*CJ U^J mH nH u h i hd CJ ^J mH nH u h i hW4 CJ ^J mH nH u j h i h- CJ U^J h i h- CJ ^J h i hB 5B*CJ ^J ph F| G| | | | | | | | |
} t} |} }} ~} } } } } } } } ~ ~ ~ O P R S ߽߈xhhXHhH h i hmP CJ ^J mH nH u h i h f CJ ^J mH nH u h i h2 CJ ^J mH nH u h i hIZ CJ ^J mH nH u h i hu CJ ^J mH nH u(h i hW4 B*CJ ^J mH nH ph u h i h(/ CJ ^J mH nH u h i hXq CJ ^J mH nH u"h i hXq >*CJ ^J mH nH u h i hW4 CJ ^J mH nH u h i hd CJ ^J mH nH u E| | }} } ~ P S E ɂ x . څ f g ( gd-
V( ^`Vgd f
V( ^`Vgd2
V( ^`Vgd f S V W G I ˂ ͂ z | 1 2 ׅ م څ e f ϿﰥpeZRh
CJ ^J h i h- CJ ^J h i hS CJ ^J h i h< 5B*CJ ^J ph h i hS 5B*CJ ^J ph $h i h< 5B*CJ ^J aJ ph h i h# CJ ^J j h i h- CJ U^J h i h# CJ ^J mH nH u h i h% CJ ^J mH nH u h i hd CJ ^J mH nH u h i hW4 CJ ^J mH nH u f g u { ! " # * + , X Y p q t øέíwwjw_T h i h"l CJ ^J h i h- CJ ^J h i h~.6 0J CJ ^J j h i h~.6 CJ U^J h i h- 5B*CJ ^J ph h i h)q[ CJ ^J h i h* CJ ^J h i h~.6 CJ ^J h i hbA CJ ^J h i h< CJ ^J h i hS CJ ^J h i hmO CJ ^J h i h< 5B*CJ ^J ph h i hS CJ ^J g u " # + s t < $If gd! < $If gd' gd
gd* Ї ч ڇ ۇ = > L M @ A P Q W e 6 7 G H ;;妛h i h
0J CJ ^J j h i h
CJ U^J h i h
CJ ^J h i h< CJ ^J h i hFT 0J CJ ^J j h i hFT CJ U^J h i hFT CJ ^J h i h"l 0J CJ ^J h i h"l CJ ^J j h i h"l CJ U^J 2 Ί Њ ڋ Č Ō ƌ ] ^ _ ` a d + , - . / 0 5 i j G )j h i h$ $ CJ U^J aJ nH tH h i h! CJ ^J aJ nH tH )j h i h! CJ U^J aJ nH tH h i h$ $ CJ ^J aJ nH tH h i hWO CJ ^J aJ h i hWO CJ ^J h i hV, CJ ^J h i h CJ ^J 4 Nj A 6 6 6 < $If gd' kd7 $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt 6 + + < $If gd' kd7 $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd! Ō e f h o 6 kd8 $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd' 6 7 9 @ i 6 kd9 $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd'
W A 6 6 6 < $If gd' kdz: $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt G V W c H I L M N p B Q R S ؒ ޣޣޣގގގ )j h i hx CJ U^J aJ nH tH )j h i h$ $ CJ U^J aJ nH tH h i hx CJ ^J aJ nH tH )j h i h! CJ U^J aJ nH tH h i h$ $ CJ ^J aJ nH tH h i h! CJ ^J aJ nH tH 3W d e g n 6 + + < $If gd' kdS; $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd! n O P R + kd,< $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd! < $If gd' R Y ! " $ + 6 kd= $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd' + R + kd= $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gdx < $If gd' + kd> $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gdx < $If gd' Ē < $If gdx < $If gd' A 6 6 6 < $If gd' kd? $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt M N Q R S x y ) * + , K L < > ? @ B C E F H I K L M ȳȳȳ٢~vrjr j[P h< Uh< jH h< U j h< UmH nH sH u hMg| j hMg| Uh$ $ CJ ^J h' hR CJ ^J aJ nH tH )j h i h$ $ CJ U^J aJ nH tH h i h$ $ CJ ^J aJ nH tH h i hR CJ ^J aJ nH tH )j h i hR CJ U^J aJ nH tH ) T U X ` 6 + + < $If gd' kdi@ $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gdR ` x $ 6 kdBA $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd' Õ 6 kdB $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd' Õ ĕ Ǖ ϕ ' , A 6 6 6 6 < $If gd' kdB $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt , - 0 8 g A 6 6 + < $If gdR < $If gd' kdC $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt g o p s x . 6 kdD $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt < $If gd' . / 2 7 K A 6 6 6 6 < $If gd' kdE $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt
A 6 6 6 6 < $If gd' kdXF $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt
: = A 6 6 6 6 < $If gd' kd1G $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt = > ? A B D E G A ? ? ? ? ? ? kd
H $$If ,\ 5.u # F B FG F
t 0 j$6 4 4
l B a p( yt G H J K Ø ̘ ͘ Θ ٘ B C D E J ] ^ _ ` $h]ha$gd6a h]h &`#$ Ø Ę ʘ ˘ ̘ Θ Ϙ ֘ ט ؘ ٘ , - @ A B C D E J ] ^ _ ` úúúÓ~me h$ $ CJ ^J !h< 56B*CJ$ ^J aJ( ph !h< 56B*CJ ^J aJ( ph hMg|
h< CJ holQ h6a 0J CJ holQ h6a CJ j holQ h6a CJ Uhx h6a CJ
h6a CJ hGg 0J mH nH u
h< 0J j h< 0J Uh<
h< CJ$ "j h< CJ$ UmH nH sH u". :p
. A!"Q#$% D y K y K p h t t p : / / w w w . u k m i . n h s . u k / u k m i / a b o u t / d e f a u l t . a s p ? p a g e R e f = 1 D Forest Pharmaceuticals20123679Armour thyroid (thyroid tablets, USP).Generic3679Armour thyroid (thyroid tablets, USP).Forest Pharmaceuticals,Inc.2012armour thyroidIn Filehttp://www.frx.com/pi/armourthyroid_pi.pdfAccessed 30/12/2013.http://www.frx.com/pi/armourthyroid_pi.pdfhttp://www.frx.com/pi/armourthyroid_pi.pdf33Acella Pharmaceuticals20103681NP Thyroid (thyroid tablets, USP).Generic3681NP Thyroid (thyroid tablets, USP).Acella Pharmaceuticals,LLC.2010armour thyroidIn Filehttp://www.npthyroid.com/ACE%2015666%20PI.pdfAccessed 30/12/2013.http://www.npthyroid.com/ACE%2015666%20PI.pdfhttp://www.npthyroid.com/ACE%2015666%20PI.pdf33RLC Labs20113680Nature-Thyroid (thyroid USP) tablets.Generic3680Nature-Thyroid (thyroid USP) tablets.RLC Labs2011armour thyroidIn Filehttp://www.nature-throid.com/images/Nature-Throid-PI-Rev041121-03.pdfAccessed 30/12/2013.http://www.nature-throid.com/images/Nature-Throid-PI-Rev041121-03.pdfhttp://www.nature-throid.com/images/Nature-Throid-PI-Rev041121-03.pdf33 D Jackson19783667Why does anyone still use desiccated thyroxine USP?Journal3667Why does anyone still use desiccated thyroxine USP?Jackson,I.M.Cobb,W.E.1978armour thyroidIn File284Am.J.Med.197864American Journal of MedicineAm.J.Med.1Lev-Ran19833677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Journal3677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Lev-Ran,A.1983armour thyroidIn File27902791Journal of the American Medical Association25020Journal of the American Medical Association1Smith19843668Desiccated thyroid preparations. Obsolete therapy.Journal3668Desiccated thyroid preparations. Obsolete therapy.Smith,S.R.1984armour thyroidIn File926927Arch.Intern.Med.144Archives of Internal MedicineArch.Intern.Med.1Royal College of Physicians.20113666The diagnosis and management of primary hypothyroidism.Generic3666The diagnosis and management of primary hypothyroidism.Royal College of Physicians.2011armour thyroidIn Filehttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfAccessed 30/12/2013.http://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdfhttp://www.rcplondon.ac.uk/sites/default/files/the-diagnosis-and-management-of-primary-hypothyroidism-revised-statement-14-june-2011_2.pdf33Vaidya20083675Management of hypothyroidism in adults.Journal3675Management of hypothyroidism in adults.Vaidya,B.Pearce,S.H.S.2008armour thyroidIn File284289Br.Med.J.337British Medical JournalBr.Med.J.1 2 D Jackson19783667Why does anyone still use desiccated thyroxine USP?Journal3667Why does anyone still use desiccated thyroxine USP?Jackson,I.M.Cobb,W.E.1978armour thyroidIn File284Am.J.Med.197864American Journal of MedicineAm.J.Med.1Lev-Ran19833677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Journal3677Part-of-the-day hypertriiodothryoninemia caused by desiccated thyroid.Lev-Ran,A.1983armour thyroidIn File27902791Journal of the American Medical Association25020Journal of the American Medical Association1Smith19843668Desiccated thyroid preparations. Obsolete therapy.Journal3668Desiccated thyroid preparations. Obsolete therapy.Smith,S.R.1984armour thyroidIn File926927Arch.Intern.Med.144Archives of Internal MedicineArch.Intern.Med.1Cooper19893719Thyroid hormone treatment: new insights into an old therapy.Journal3719Thyroid hormone treatment: new insights into an old therapy.Cooper,D.S.1989armour thyroidIn File26942695Journal of the American Medical Association26118Journal of the American Medical Association1` D Sawin19783720A comparison of thyroxine and desiccated thyroid in patients with primary hypothyrodism.Journal3720A comparison of thyroxine and desiccated thyroid in patients with primary hypothyrodism.Sawin,C.T.Hershman,J.M.Fernandez-Garcia,R.Ghazvinian,S.1978armour thyroidIn File15181525Metabolism2710Metabolism1Singh19723721Desiccated thryoid and levothyroxine in hypothyroidism.Journal3721Desiccated thryoid and levothyroxine in hypothyroidism.Singh,S.P.Feldman,E.B.Carter,A.C.1972armour thyroidIn File10451048N.Y.State J.Med.MayNew York State Journal of MedicineN.Y.State J.Med.1Sturnick1961946A comparison of the effect of desiccated thyroid and sodium levothyroxine on the serum protein-bound iodine.Journal946A comparison of the effect of desiccated thyroid and sodium levothyroxine on the serum protein-bound iodine.Sturnick,M.I.Lesses,M.F.1961armour thyroidIn File608609N.Engl.J.Med.26412New England Journal of MedicineN.Engl.J.Med.1McGavack19563722Therapeutic activity of desiccated thyroid substance, sodium L-thyroxine and D,L-triiodothyronine. A comparative study.Journal3722Therapeutic activity of desiccated thyroid substance, sodium L-thyroxine and D,L-triiodothyronine. A comparative study.McGavack,T.H.Reckendorf,H.K.1956armour thyroidIn File774777Am.J.Med.MayAmerican Journal of MedicineAm.J.Med.1 D y K y K . h t t p : / / w w w . r c p l o n d o n . a c . u k / s i t e s / d e f a u l t / f i l e s / t h e - d i a g n o s i s - a n d - m a n a g e m e n t - o f - p r i m a r y - h y p o t h y r o i d i s m - r e v i s e d - s t a t e m e n t - 1 4 - j u n e - 2 0 1 1 _ 2 . p d f yX; H,]ą'c $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt $$If !v h#v #v#vG#v:V ,
t 0 j$6 5 5 5G5B p( yt x D d
D
C A n h s b {7 zv7 2% 'I n {7 zv7 2%PNG
IHDR V # 9g
PLTEߧߝަؕߞܔ֖Ԕދؔʄ~{փyrssmskpnjdb[\L[^VWPGPPLHDE::.3:5&* ,{!|#z!||%v!st wr y u rs s smo l l l f j
f e a ` otRNS Vv bKGD H gIFg >U cmPPJCmp0712 H s .IDATHKV_GqB
Z+#QiFZq40;aV>;;01
Sm]!JZr-^KggR\: 5co7
%j ҼFϕe@dR1m]-*ӬMM?y)5XlMj11۔ ~{ jdAhXnvBX>g:݇o`z8ȮZK%e*2<-xK eztƼl fmJ?'_fBϛ!\pp98 >iT
﮴ʾb -[>OƧmj`Fvc Ge]ˣЕP,¼C 4ū*t(bC#ӘM +X: #`]PW.$' l7[1qH(Y@%$t!.ʁ=E6QrpE3xV1Ap~7 )P`q&aڿ8,;a&-m#*
1.BvkW,FAӂc&8 ۃ$|)*} woh+X_23'VNx7gen
KL o~Nh2>1,5hkh/F JOAZ%PN~pUNRq0N0`bX#2BWe!;7q#"+1_E6#KDa@Օ冓
{þuz.IWtၮWBkgEu]4A1`pQMMVu~[8L\\x"а\57x!GI꘤nٺOX'{bwh[*b'-XT
W$D);u:2&~"/$MqHbBp>uVRG Κ۾Q2{U cmPPJCmp0712 Om IIDATHU_h[U{.u7*BqLM2(M|{)ˆa/:= ,6ut0зT9F
4M69~me 9WGٺ:
v*lRz먐:DTuX' FI3N@=J$Q0K'xEA:՜ƂzںO$CZuʏ( VW.n ó9LA bQ3gݛ$2U ҂ b?";'6awy"*+ƔX.(:0@>wH]cń 6V;̤u_l`x?xxyۙ
s]33?,+}֠g
Ͻ¼A9?lۑ$҉\k_ #f I[^~pdT`Q37mzB^`֝ /XJ֡#v-f2̺v'ipC IENDB` ^ 6 6 6 6 6 6 6 6 6 v v v v v v v v v 6 6 6 6 6 > 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 h H 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 2 0 @ P ` p 2 ( 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 0 @ P ` p 8 X V ~ _HmH nH sH tH D ` D N o r m a l CJ OJ QJ _HmH sH tH X @ X H e a d i n g 1 $
& F
h< @& 5CJ KH T @ T H e a d i n g 2 $
& F < @&
5CJ V @ V H e a d i n g 3 $
& F < @&
56CJ P @ P H e a d i n g 4 $
& F < @&
CJ H H H e a d i n g 5
& F < @&
n T @ T H e a d i n g 6
& F < @&
6OJ QJ L @ L H e a d i n g 7
& F < @&
CJ P @ P H e a d i n g 8
& F < @&
6CJ R @ R H e a d i n g 9
& F < @&
56CJ D A` D D e f a u l t P a r a g r a p h F o n t V i@ V
0 T a b l e N o r m a l :V 4 4
l a ( k (
0 N o L i s t 8 @ 8 F o o t e r
9r CJ < @ < H e a d e r
9r 6CJ D B@ D B o d y T e x t B*CJ mH ph sH . )@ !. P a g e N u m b e r 6 U`16 H y p e r l i n k >*B*ph F V`AF F o l l o w e d H y p e r l i n k >*B* ph D RD L i s t P a r a g r a p h
^m$ H @ bH B a l l o o n T e x t CJ OJ QJ ^J aJ B '`qB n C o m m e n t R e f e r e n c e CJ aJ L @ L n C o m m e n t T e x t CJ OJ QJ mH sH tH B oB n C o m m e n t T e x t C h a r OJ QJ L j@L
s 0 C o m m e n t S u b j e c t 5OJ QJ \tH R oR s 0 C o m m e n t S u b j e c t C h a r 5OJ QJ \tH j j )q[
T a b l e G r i d 7 :V 0 PK ! [Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;r ØJB+$G]7O٭V$ !)O^rC$y@ /yH*)UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSe bORD۫qu gZo~ٺlAplxpT0+[}`j zA V2Fi@qv֬5\|ʜ̭NleXd sjcs7f
W+Ն7` g ȘJj|h(KD-
dXiJ؇(x$( :;˹! I_TS 1?E ??ZBΪmU/ ?~xY'y5g&/ɋ>GMGeD3Vq%'#q$8K )fw 9:ĵ
x}rxwr:\TZaG*y8IjbRc|XŻǿI
u3KGnD 1NIBs
RuK>V.E L+M2#'fi ~V vl{u8z H
* :( W ☕
~JTe\O*tHGHY }KNP*ݾ˦ TѼ9/#A7qZ $*c?qUnwN%Oi4 =3N)cbJ
uV4(Tn
7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5 qpN8KGbe
Sd̛\17 pa>SR!
3 K4'+rzQ
TTIIvt]Kc⫲K#v5+|D~ O@%\w_nN[L9KqgVhn
R!y+Un;*&/HrT >>\
t=.Tġ
S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y ; ̠[MCۿhf]o{oY=1kyV V5E8Vk+֜\80X4D)!!?*|fv
u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/ PK !
ѐ ' theme/theme/_rels/themeManager.xml.relsM
0wooӺ&݈Э5
6?$Q
,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{ P8g/ ]QAsم(#L[ PK- ! [Content_Types].xmlPK- ! ֧ 6 0 _rels/.relsPK- ! ky theme/theme/themeManager.xmlPK- ! 0C) theme/theme/theme1.xmlPK- !
ѐ ' theme/theme/_rels/themeManager.xml.relsPK ]
` ` t ( 3 # ) V+ , / 0 C6 8 Z9 ? D bH uM S X ^\ Pc f Bj o Lu Py F| S f G ` M O P Q S T U V W X Y Z [ \ ] ^ _ a b c d e f h i j k l m o p r s y C e E| g W n R + ` Õ , g . = G ` N R ` g n q t u v w x z { | } ~ P > B v z f$ z$ $ $ $ '
( #( $( /( ( ( ( ( ( e) - - / / 0 0 0 1 l6 q6 uE H H RM xP |P U X X Rp ip p bq q | +~ X~ p~ ~ ~ ~ ~ ~ = L @ P 6 G Ń ] _ + / i H L R M Q x ) + K ` XXQQ4QQQDQQDQQDQQQDQQQQtQXĕXXXXXXXXXXXXXXXXXXXXXX ! !tX @ @ . (
b B
c $ D V " ? t
3 S " ? ?
0 (
B
S ? u U t D q D u
_ H l t 1 7 0 2 0 2 2 5 4
_ H l t 1 7 0 2 0 2 2 5 5
_ H l t 2 1 9 0 1 3 3 4 8
_ H l t 2 1 9 0 1 3 3 4 9
_ H l t 2 4 0 8 7 3 0 5 9
_ H l t 2 4 0 8 7 3 0 6 0
_ H l t 4 4 3 9 8 6 1 5 7
_ H l t 4 4 3 9 8 6 1 5 8 q q a @ @ @ @ @ @ @ @ q q a ? A B D E G H J K D E ^ a " " U# Y# 0 "0 ]7 o7 J[ N[ m m n n ? A B D E G H J K D E ^ a 3 3 3 3 3 3 3 3 3 [ [ O P Q V
3 4 5" F" " " V# Y# # # $ $ e$ f$ $ $ $ % % % Y% Y% Z% Z% % % B& B& '( .( ( ( ( ( - - 0 0 0 0 o6 p6 b7 b7 < #= $= $= H H zP {P Q Q X X Z Z )[ )[ #\ #\ \ \ r] r] =b Bb hi hi Um Um m m m m m m n n n n n n n s s s s kt kt t t u Ov Sv Sv v v v v Ww Ww Yw Yw w w w w x x x x Gy Gy Ky Ky y y y y zz zz ~z ~z 2{ 2{ 4{ 4{ { { | | | | | | | | e} g} ~ ~ > ? ? B B Ï ˏ Ώ ؏ ُ B a ]jFJo |P $od MO
l kg
} 1XX - + Mk&p U, .
`^J=. u O. ;PQp>S Hf*]7x pgi&
k~+ * h ^`B* OJ QJ o( ph h H h ^`OJ QJ ^J o( h H o h p p^p`OJ QJ o( h H h @ @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P P^P`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h p p^p`OJ QJ o( h H h @ @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P P^P`OJ QJ o( h H h h h^h`OJ QJ o( h 8 8^8`OJ QJ o( o h ^`OJ QJ o( h ^ `OJ QJ o( h ^ `OJ QJ o( o h x x^x`OJ QJ o( h H H^H`OJ QJ o( h ^`OJ QJ o( o h ^`OJ QJ o( ^`o( ) ^`OJ PJ QJ ^J )
pL^p`Lh H .
@ ^@ `h H .
^`h H .
L^`Lh H .
^`h H .
^`h H .
PL^P`Lh H . h ^`OJ QJ o( h ^`OJ QJ ^J o( h H o h p^p`OJ QJ o( h H h @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P^P`OJ QJ o( h H h h^h` . h ^`B* OJ QJ o( ph h H h ^`OJ QJ ^J o( h H o h p p^p`OJ QJ o( h H h @ @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P P^P`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h p^p`OJ QJ o( h H h @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P^P`OJ QJ o( h H h h^h` . ^`o( )
^`h H .
pL^p`Lh H .
@ ^@ `h H .
^`h H .
L^`Lh H .
^`h H .
^`h H .
PL^P`Lh H . ^`o( )
^`h H .
pL^p`Lh H .
@ ^@ `h H .
^`h H .
L^`Lh H .
^`h H .
^`h H .
PL^P`Lh H . h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h p^p`OJ QJ o( h H h @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P^P`OJ QJ o( h H ^` ^` . ^` . . ^` . . . ^` . . . . ^` . . . . .
^`
. . . . . .
^` . . . . . . .
p^` . . . . . . . . ^`OJ PJ QJ ^J )
^`h H .
pL^p`Lh H .
@ ^@ `h H .
^`h H .
L^`Lh H .
^`h H .
^`h H .
PL^P`Lh H . h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h p^p`OJ QJ o( h H h @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P^P`OJ QJ o( h H h ^`B* OJ QJ o( ph h H h ^`OJ QJ ^J o( h H o h p p^p`OJ QJ o( h H h @ @ ^@ `OJ QJ o( h H h ^`OJ QJ ^J o( h H o h ^`OJ QJ o( h H h ^`OJ QJ o( h H h ^`OJ QJ ^J o( h H o h P P^P`OJ QJ o( h H ;PQ 1XX U, ;PQ ;PQ $ | k~ - ]jF HMk& u O MO
. pgi Hf*] `^J kg
$ @ h ^`OJ QJ o( \;0 d0 ^ vm ?
5[# $ j j [#J3 J3 Z4eMb gRRZ4 CvReMb , O9)YZ4 eMb5 &fZ4 7$BkZ4 @ I ;N 3 Um m R =" M( \0 j A {y qz k N y S~ ' a x K M ( s\ 6 3} / mO S Z J, o: . N FT X v u * # h " +4 9 oh v O7 D XE J u v! 9# $ $ 2$ 3$ g% '% 4% g& ' $(' T' c' =( ?( n( oN) * * D8* W* C+ K+ V, - (- U- r7. of. (/ 2/ 0 1 O1 _&2 52 _2 |2 3 4 5 5 5B5 6 x+6 ~.6 r8 AE9 M>: (Y: ~o: \; < < "< C= h= p= `> u> `? / ? )? C @ Y@ 1A eAA KA bA /C ~E F p_F G H t.H nH 6I !J VOJ dK HK =K 0K RL gM @fN [O WO }P .P M~P (Q 7Q :Q _Q RR l S $S 0T HT ;U ?[U YV PKW TW SxW 9Y ZY IZ W[ )q[ "\ "] R2] `] ^ m^
_ 7_ =_ |_
` !` S` 6a Aa X1b YJb c lsd 2e 1Le Oe hf /8f Gg R~g =)h *3h i Gi Yi -Xj k +k
8k l "l 8l om n r;n {Qn on vn o \o
p yq !r .r ]t YWu +v zv @x Zy V{ | [| Mg| q} 0 ~ ~ ~ N )\ H |U ot / 3 M il k qu / + B m f l @ !~ $ % A K V fY n h 3 O ! 0 O @\ cs H M) y/ cD a 8 Jo ( N l rU 6 X9 )H mP
b V& ` ?5 w7 6 :B ] 0E & te Z x ~
X
@+ oU u7 I
d D 6} V ` : k_ 0 / d| ; _F D lg t gB I f s i ' B m 0O BA kR !d S l~
d< A P Y P + G M S
r, |I f x
mf - F ^ ~] |
Q u d , ^M 1G b k }% "X Y p 3 4 0 # c X3 Sq f m z 6 * C Iw 5 R F { C R! 3
# A iO r i < C y 2 WH
P Xq 2 \: W4
? q ? A R E F M G R . I n s t a n t F o r m a t
R E F M G R . L a y o u t R E F M G R . L i b r a r i e s w < E N I n s t a n t F o r m a t > < E n a b l e d > 1 < / E n a b l e d > < S c a n U n f o r m a t t e d > 1 < / S c a n U n f o r m a t t e d > < S c a n C h a n g e s > 1 < / S c a n C h a n g e s > < / E N I n s t a n t F o r m a t > B< E N L a y o u t > < S t y l e > v a n c o u v e r Q & a m p ; A < / S t y l e > < L e f t D e l i m > { < / L e f t D e l i m > < R i g h t D e l i m > } < / R i g h t D e l i m > < F o n t N a m e > A r i a l < / F o n t N a m e > < F o n t S i z e > 9 < / F o n t S i z e > < R e f l i s t T i t l e > < / R e f l i s t T i t l e > < S t a r t i n g R e f n u m > 1 < / S t a r t i n g R e f n u m > < F i r s t L i n e I n d e n t > 0 < / F i r s t L i n e I n d e n t > < H a n g i n g I n d e n t > 0 < / H a n g i n g I n d e n t > < L i n e S p a c i n g > 0 < / L i n e S p a c i n g > < S p a c e A f t e r > 1 < / S p a c e A f t e r > < R e f l i s t O r d e r > 0 < / R e f l i s t O r d e r > < C i t a t i o n O r d e r > 0 < / C i t a t i o n O r d e r > < N u m b e r R e f e r e n c e s > 1 < / N u m b e r R e f e r e n c e s > < S h o w R e c o r d I D > 0 < / S h o w R e c o r d I D > < S h o w N o t e s > 0 < / S h o w N o t e s > < S h o w A b s t r a c t > 0 < / S h o w A b s t r a c t > < S h o w R e p r i n t > 0 < / S h o w R e p r i n t > < S h o w K e y w o r d s > 0 < / S h o w K e y w o r d s > < / E N L a y o u t > O < E N L i b r a r i e s > < L i b r a r i e s > < i t e m > m a i n r e f m a n v 1 2 < / i t e m > < / L i b r a r i e s > < / E N L i b r a r i e s > @ ( f g ` @ n @ U n k n o w n G * Ax T i m e s N e w R o m a n 5 S y m b o l 3. * Cx A r i a l 7. @ C a l i b r i 5. . [` ) T a h o m a ?= * Cx C o u r i e r N e w ; W i n g d i n g s A $ B C a m b r i a M a t h " h 3$C\$C#C a y I a y I q 20 բ{ - 3q HP $P 6a 2 ! x x Y C : \ D o c u m e n t s a n d S e t t i n g s \ k a t e \ M y D o c u m e n t s \ W o r k \ F A Q P r o c e s s \ M e d i c i n e s Q & A T e m p l a t e 3 . d o t U K M i Q & A x x K a t e P i c k e t t S h e e n a V i t h l a n i P
Oh +'0 $
D P \
h t | UKMi Q&A xx Kate Pickett Medicines Q&A Template 3 Sheena Vithlani 7 Microsoft Office Word @ ԭ @ '*v@ 6v@ 2;v a y ՜. +,D ՜. +,D h p
NWLH NHS Trust I UKMi Q&A xx Title 8 @ _PID_HLINKS A $ < w h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 6 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d $ ? t h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 5 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d $ 9 q h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 3 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d $ 8 n h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 2 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d $ ; k h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 1 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d $ : h h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 0 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d P e h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 9 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d Q b h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 8 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d ^ _ h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 7 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d \ \ h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 5 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d ] Y h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 4 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d Z V h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 3 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d [ S h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 2 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d X P h t t p : / / w w w . l i b r a r y . n h s . u k / h d a s / s e a r c h - r e s u l t s / 1 ? P a g e N u m b e r = 1 & P a g e S i z e = 5 0 & S o r t B y = s r t . u n s p e c i f i e d & S h o w A b s t r a c t s = T r u e & d a t a b a s e s = b n j . o v i . a m e d T M h t t p : / / w w w . g o o g l e . c o . u k / M J " h t t p : / / w w w . m e d i c i n e s c o m p l e t e . c o m / = 0 G h t t p : / / w w w . m h r a . g o v . u k / < b D + h t t p : / / w w w . b r i t i s h t h y r o i d - a s s o c i a t i o n . o r g / s ( A h t t p : / / w w w . s i g n . a c . u k / ! ? > h t t p : / / w w w . n i c e . o r g . u k / ! " ; h t t p : / / w w w . e v i d e n c e . n h s . u k / ) 8 m a i l t o : l n w h - t r . m e d i n f o @ n h s . n e t U & 4 h t t p : / / w w w . r c p l o n d o n . a c . u k / s i t e s / d e f a u l t / f i l e s / t h e - d i a g n o s i s - a n d - m a n a g e m e n t - o f - p r i m a r y - h y p o t h y r o i d i s m - r e v i s e d - s t a t e m e n t - 1 4 - j u n e - 2 0 1 1 _ 2 . p d f ` } ; h t t p : / / w w w . u k m i . n h s . u k / a c t i v i t i e s / m e d i c i n e s Q A s / d e f a u l t . a s p | i 8 h t t p : / / w w w . u k m i . n h s . u k / u k m i / a b o u t / d e f a u l t . a s p ? p a g e R e f = 1 ! " h t t p : / / w w w . e v i d e n c e . n h s . u k /
! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q R S T U V W X Y Z [ \ ] ^ _ ` a b c d e f g h i j k l m n o p q r s t u v w x y z { | } ~
R o o t E n t r y F ?YE;v D a t a
bV 1 T a b l e e W o r d D o c u m e n t
0 S u m m a r y I n f o r m a t i o n ( D o c u m e n t S u m m a r y I n f o r m a t i o n 8 M s o D a t a S t o r e rJE;vp VE;v 0 V G P C O N R I A = = 2 rJE;vp VE;v I t e m
P r o p e r t i e s U M a c r o s p VE;vp VE;v V B A
p VE;vp VE;v
! " # $ & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ; < = > ? @ A B C D E F G H I J K L M N O P Q S T U V W X [
0* pH d ProjectQ ( @=
l xX J<
rstdole>s t d o l eP
h %^ * \G{00020430- C
0046}# 2.0#0#C: \Windows \system32\e2.tlb #OLE Automation ` ENormalENCr m aQF *,\C
vm A!OfficgOD f i cg !G{2DF 8D04C-5B FA-101B-BDE5gAAe42ggra m Files\@CommonM icrosoft Shared\ OFFICE14 \MSO.DLd i r
T h i s D o c u m e n t _ V B A _ P R O J E C T % & P R O J E C T R L#M 14.0 Ob Library% xMSFAs> AM S FBs$ 3@ dD4 52EE1-E0D8F0A-8 - 02608C4D0BB4dFM260L'B p&/ ; "1 D|~ AC00}#0B# 0 @ 4EC0E90 1-D1C5-4 674-8EBD- bE2B9672CEH.User s\ALEXAN ~1\AppDa ta\Local \Temp\Wo`rd8.0[B0.xexd\U5@# .E
.`M " ThisDo cumentG
T@i s "D ec ue n@ 2 H 1bu ",o""+ o x ME ( S" S S" < ( 1 N o r m a l . T h i s D o c u m e n t 8 ( % H x Attribut e VB_Nam e = "Thi sDocument"
Bas1Normal.VGlobal!SpaclFalse Creatabl Pre decla Id Tru
BExpose Temp lateDeriv$Custom izC1 a * \ G { 0 0 0 2 0 4 E F - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 4 . 1 # 9 # C : \ P R O G R A ~ 1 \ C O M M O N ~ 1 \ M I C R O S ~ 1 \ V B A \ V B A 7 \ V B E 7 . D L L # V i s u a l B a s i c F o r A p p l i c a t i o n s * \ G { 0 0 0 2 0 9 0 5 - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 8 . 5 # 0 # C : \ P r o g r a m F i l e s \ M i c r o s o f t O f f i c e \ O f f i c e 1 4 \ M S W O R D . O L B # M i c r o s o f t W o r d 1 4 . 0 O b j e c t L i b r a r y * \ G { 0 0 0 2 0 4 3 0 - 0 0 0 0 - 0 0 0 0 - C 0 0 0 - 0 0 0 0 0 0 0 0 0 0 4 6 } # 2 . 0 # 0 # C : \ W i n d o w s \ s y s t e m 3 2 \ s t d o l e 2 . t l b # O L E A u t o m a t i o n * \ C N o r m a l * \ C N o r m a l vX (* \ G { 2 D F 8 D 0 4 C - 5 B F A - 1 0 1 B - B D E 5 - 0 0 A A 0 0 4 4 D E 5 2 } # 2 . 5 # 0 # C : \ P r o g r a m F i l e s \ C o m m o n F i l e s \ M i c r o s o f t S h a r e d \ O F F I C E 1 4 \ M S O . D L L # M i c r o s o f t O f f i c e 1 4 . 0 O b j e c t L i b r a r y * \ G { 0 D 4 5 2 E E 1 - E 0 8 F - 1 0 1 A - 8 5 2 E - 0 2 6 0 8 C 4 D 0 B B 4 } # 2 . 0 # 0 # C : \ W i n d o w s \ s y s t e m 3 2 \ F M 2 0 . D L L # M i c r o s o f t F o r m s 2 . 0 O b j e c t L i b r a r y * \ G { 4 E C 0 E 9 0 1 - D 1 C 5 - 4 6 7 4 - 8 E B D - B F A E 2 B 9 6 7 2 C E } # 2 . 0 # 0 # C : \ U s e r s \ A L E X A N ~ 1 \ A p p D a t a \ L o c a l \ T e m p \ W o r d 8 . 0 \ M S F o r m s . e x d # M i c r o s o f t F o r m s 2 . 0 O b j e c t L i b r a r y .E
.`M xX T h i s D o c u m e n t 0 7 5 8 7 f 5 3 3 5 # T h i s D o c u m e n t o 74N@jl ` & Wordk VBA Win16~ Win32 Win64x Mac VBA6# VBA7# Project- stdole` Normal Officeu MSFormsC ThisDocument< _Evaluate Documentj ` #
ID="{19167558-71E3-48D4-8217-12D1DC870EF2}"
Document=ThisDocument/&H00000000
Name="Project"
HelpContextID="0"
VersionCompatible32="393222000"
CMG="0D0FAABBBACCBECCBECCBECCBE"
DPB="1A18BDB2CBB3CBB3CB"
GC="272580C180C38CC48CC473"
[Host Extender Info]
&H00000001={3832D640-CF90-11CF-8E43-00A0C911005A};VBE;&H00000000
&H00000002={000209F2-0000-0000-C000-000000000046};Word8.0;&H00000000
ThisDocument T h i s D o c u m e n t
F Microsoft Word 97-2003 Document
MSWordDoc Word.Document.8 9q P R O J E C T w m Y ) C o m p O b j Z r